Cargando…

In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients

BACKGROUND: Fibroblast growth factor receptor (FGFR2) has been proposed as a target in gastric cancer. However, appropriate methods to select patients for anti-FGFR2 therapies have not yet been established. METHODS: We used in situ techniques to investigate FGFR2 mRNA expression and gene amplificati...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuboki, Yasutoshi, Schatz, Christoph A., Koechert, Karl, Schubert, Sabine, Feng, Janine, Wittemer-Rump, Sabine, Ziegelbauer, Karl, Krahn, Thomas, Nagatsuma, Akiko Kawano, Ochiai, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906494/
https://www.ncbi.nlm.nih.gov/pubmed/28852882
http://dx.doi.org/10.1007/s10120-017-0758-x
_version_ 1783315380820770816
author Kuboki, Yasutoshi
Schatz, Christoph A.
Koechert, Karl
Schubert, Sabine
Feng, Janine
Wittemer-Rump, Sabine
Ziegelbauer, Karl
Krahn, Thomas
Nagatsuma, Akiko Kawano
Ochiai, Atsushi
author_facet Kuboki, Yasutoshi
Schatz, Christoph A.
Koechert, Karl
Schubert, Sabine
Feng, Janine
Wittemer-Rump, Sabine
Ziegelbauer, Karl
Krahn, Thomas
Nagatsuma, Akiko Kawano
Ochiai, Atsushi
author_sort Kuboki, Yasutoshi
collection PubMed
description BACKGROUND: Fibroblast growth factor receptor (FGFR2) has been proposed as a target in gastric cancer. However, appropriate methods to select patients for anti-FGFR2 therapies have not yet been established. METHODS: We used in situ techniques to investigate FGFR2 mRNA expression and gene amplification in a large cohort of 1036 Japanese gastric cancer patients. FGFR2 mRNA expression was determined by RNAscope. FGFR2 gene amplification was determined by dual-color in situ hybridization (DISH). RESULTS: We successfully analyzed 578 and 718 samples by DISH and RNAscope, respectively; 2% (12/578) showed strong FGFR2 gene amplification (FGFR2:CEN10 >10); moderate FGFR2 gene amplification (FGFR2:CEN10 <10; ≥2) was detected in 8% (47/578); and high FGFR2 mRNA expression of score 4 (>10 dots/cell and >10% of positive cells with dot clusters under a 20× objective) was seen in 4% (29/718). For 468 samples, both mRNA and DISH data were available. FGFR2 mRNA expression levels were associated with gene amplification; FGFR2 mRNA levels were highest in the highly amplified samples (n = 12). All highly amplified samples showed very strong FGFR2 mRNA expression (dense clusters of the signal visible under a 1× objective). Patients with very strong FGFR2 mRNA expression showed more homogeneous FGFR2 mRNA expression compared to patients with lower FGFGR2 mRNA expression. Gastric cancer patients with tumors that had an FGFR2 mRNA expression score of 4 had shorter RFS compared with score 0–3 patients. CONCLUSION: RNAscope and DISH are suitable methods to evaluate FGFR2 status in gastric cancer. Formalin-fixed paraffin-embedded (FFPE) tissue slides allowed evaluation of the intratumor heterogeneity of these FGFR2 biomarkers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10120-017-0758-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5906494
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Japan
record_format MEDLINE/PubMed
spelling pubmed-59064942018-04-20 In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients Kuboki, Yasutoshi Schatz, Christoph A. Koechert, Karl Schubert, Sabine Feng, Janine Wittemer-Rump, Sabine Ziegelbauer, Karl Krahn, Thomas Nagatsuma, Akiko Kawano Ochiai, Atsushi Gastric Cancer Original Article BACKGROUND: Fibroblast growth factor receptor (FGFR2) has been proposed as a target in gastric cancer. However, appropriate methods to select patients for anti-FGFR2 therapies have not yet been established. METHODS: We used in situ techniques to investigate FGFR2 mRNA expression and gene amplification in a large cohort of 1036 Japanese gastric cancer patients. FGFR2 mRNA expression was determined by RNAscope. FGFR2 gene amplification was determined by dual-color in situ hybridization (DISH). RESULTS: We successfully analyzed 578 and 718 samples by DISH and RNAscope, respectively; 2% (12/578) showed strong FGFR2 gene amplification (FGFR2:CEN10 >10); moderate FGFR2 gene amplification (FGFR2:CEN10 <10; ≥2) was detected in 8% (47/578); and high FGFR2 mRNA expression of score 4 (>10 dots/cell and >10% of positive cells with dot clusters under a 20× objective) was seen in 4% (29/718). For 468 samples, both mRNA and DISH data were available. FGFR2 mRNA expression levels were associated with gene amplification; FGFR2 mRNA levels were highest in the highly amplified samples (n = 12). All highly amplified samples showed very strong FGFR2 mRNA expression (dense clusters of the signal visible under a 1× objective). Patients with very strong FGFR2 mRNA expression showed more homogeneous FGFR2 mRNA expression compared to patients with lower FGFGR2 mRNA expression. Gastric cancer patients with tumors that had an FGFR2 mRNA expression score of 4 had shorter RFS compared with score 0–3 patients. CONCLUSION: RNAscope and DISH are suitable methods to evaluate FGFR2 status in gastric cancer. Formalin-fixed paraffin-embedded (FFPE) tissue slides allowed evaluation of the intratumor heterogeneity of these FGFR2 biomarkers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10120-017-0758-x) contains supplementary material, which is available to authorized users. Springer Japan 2017-08-29 2018 /pmc/articles/PMC5906494/ /pubmed/28852882 http://dx.doi.org/10.1007/s10120-017-0758-x Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Kuboki, Yasutoshi
Schatz, Christoph A.
Koechert, Karl
Schubert, Sabine
Feng, Janine
Wittemer-Rump, Sabine
Ziegelbauer, Karl
Krahn, Thomas
Nagatsuma, Akiko Kawano
Ochiai, Atsushi
In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients
title In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients
title_full In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients
title_fullStr In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients
title_full_unstemmed In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients
title_short In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients
title_sort in situ analysis of fgfr2 mrna and comparison with fgfr2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906494/
https://www.ncbi.nlm.nih.gov/pubmed/28852882
http://dx.doi.org/10.1007/s10120-017-0758-x
work_keys_str_mv AT kubokiyasutoshi insituanalysisoffgfr2mrnaandcomparisonwithfgfr2genecopynumberbydualcolorinsituhybridizationinalargecohortofgastriccancerpatients
AT schatzchristopha insituanalysisoffgfr2mrnaandcomparisonwithfgfr2genecopynumberbydualcolorinsituhybridizationinalargecohortofgastriccancerpatients
AT koechertkarl insituanalysisoffgfr2mrnaandcomparisonwithfgfr2genecopynumberbydualcolorinsituhybridizationinalargecohortofgastriccancerpatients
AT schubertsabine insituanalysisoffgfr2mrnaandcomparisonwithfgfr2genecopynumberbydualcolorinsituhybridizationinalargecohortofgastriccancerpatients
AT fengjanine insituanalysisoffgfr2mrnaandcomparisonwithfgfr2genecopynumberbydualcolorinsituhybridizationinalargecohortofgastriccancerpatients
AT wittemerrumpsabine insituanalysisoffgfr2mrnaandcomparisonwithfgfr2genecopynumberbydualcolorinsituhybridizationinalargecohortofgastriccancerpatients
AT ziegelbauerkarl insituanalysisoffgfr2mrnaandcomparisonwithfgfr2genecopynumberbydualcolorinsituhybridizationinalargecohortofgastriccancerpatients
AT krahnthomas insituanalysisoffgfr2mrnaandcomparisonwithfgfr2genecopynumberbydualcolorinsituhybridizationinalargecohortofgastriccancerpatients
AT nagatsumaakikokawano insituanalysisoffgfr2mrnaandcomparisonwithfgfr2genecopynumberbydualcolorinsituhybridizationinalargecohortofgastriccancerpatients
AT ochiaiatsushi insituanalysisoffgfr2mrnaandcomparisonwithfgfr2genecopynumberbydualcolorinsituhybridizationinalargecohortofgastriccancerpatients